Wine rating is best performed under blinded conditions. Surprisingly, it is sometimes not possible to distinguish white from red wines when blindfolded. Knowing that the wine is expensive increases the client's appreciation. The risks of migraine attacks and hangover are not estimated in the ratings, and we look to unbiased experts' books and columns before shopping (Van Zyl, et al., 2008) . However, how do we know whether one wine is just as good as another?
That question may not go down well with competitive wine merchants. Drug regulators, although, request data to show that one treatment is no better or worse than another. As with wine quality, that cannot be established with mathematical accuracy, a certain degree of flexibility is accepted, provided that the drug data are of comparable quality.
Drug regulators were primarily concerned with drug safety rather than efficacy. FDA came about in 1938 when many patients died from a pharmacy contamination of sulphanilamide. Following the thalidomide teratogenicity disaster in 1956-1962, a solid regulatory foundation was laid for assessing the utility of human medicines by strict standards. This now governs all aspects of drug testing. The first version of the Declaration of Helsinki was composed by the World Medical Association in 1964 to provide a universal guideline for ethics review committees to assess the merits of drug trial protocols based on patient consent and protection.
In the EU, regulation for the supervision of human medicines was centralized in 1993 in the European Medicines Agency. The pharmaceutical industry, in consort with regulatory agencies, formulated a code of trial conduct (Good Clinical Practice) that ascertained methods for selecting patients, measuring and recording the efficacy and safety of treatments, audit trails for controlling data quality, source data verification, monitoring, etc. Research ethics are now governed by law in some countries. Increasingly, to bring about innovative therapies, the clinician has to cope with a technology that has distanced itself from the ordinary world of clinical medicine. It has moved into specialized units for drug testing.
One aspect in this new environment for clinical drug research is that of the ethics of placebo. Following a WMA meeting at the University of Pretoria, the Declaration of Hel-sinki was revised in 2000, and its 29th paragraph became the subject of controversy: 'the benefits, risks, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic and therapeutic methods'. Thoughtful statisticians commented that to show a difference between two active treatments it requires much larger sample sizes than those required for valid comparisons with placebo, thus exposing many more subjects, the nonresponders, to remain ill (Leon and Solomon, 2003) . A partial solution to this dilemma is to randomize more patients to active treatments than to placebo. Another solution was proposed by Fisher, et al. (2001) , estimating the effect of a 'putative placebo' by means of odds ratio as if a placebo arm had been in a trial. Following a period of debate, the WMA issued a note of clarification that placebo can be accepted for a minor condition that does not pose any additional risk of serious or irreversible harm. Currently, a WMA task force with members from Brazil, Japan, Sweden, South Africa and Germany has been appointed to revise the Declaration for adoption by the WMA general assembly in October 2008.
Hence, one of the latest concepts in clinical trial design for drug regulation is that of noninferiority. In the absence of a placebo arm, how does one determine whether two active treatments are similarly safe and effective or not? It cannot be done with certainty. The words equivalence and superiority are more palatable than noninferiority, but noninferiority is the preferred term in reporting trials (Piaggio, et al., 2006) . This term first appeared on PubMed in 1998, and now has less than 500 entries (there are 250,000 entries for the term randomized control trial, 5600 of which are on psychotropic drugs).
In 2005, the European Medicines Agency issued a guideline on the choice of the noninferiority margin stating at the outset that 'a noninferiority trial aims to show that the test product is not worse than the comparator by more than a prespecified, small amount. This amount is known as the noninferiority margin, or delta'. This approach to experimental data is further explained in two of the articles in this issue of the journal Nutt, et al., 2008) .
One reason why noninferiority has become an issue in recent years is the increasing number of medicines with similar efficacy, such as the serotonin reuptake inhibitors and the antimicrobials. With regard to the latter, the FDA has observed that many noninferiority studies were launched in selfresolving diseases (upper respiratory infections) in which the benefit of antimicrobials is negligible. Meta-analyses of these trials compound the issue in that they are based on studies with differing disease definitions, inclusion criteria and endpoints (Powers, et al., 2005) . There is concern that this practice inflates resistance to antimicrobials and so may have contributed to this current public health crisis (Leading Edge, 2008) .
What, then, is delta? The consensus guideline in this journal attempts to explain this and to apply a delta analysis to a noninferiority study of duloxetine and venlafaxine in adults with generalized anxiety disorder. Although one needs to digest some tongue-twisting noninferiority math to even begin to understand this, the clinician can rest assured that his or her experience and judgement are fundamental to the process of assessing whether one treatment is no better or worse than another. The proof of the pudding is precisely that: clinical judgement is crucial to establish the noninferiority margin (delta). Clinicians should select a delta that allows a high degree of certainty that the drug is better than placebo while ensuring that any loss in efficacy is clinically acceptable. This choice is based on the current knowledge about the disease, clinical judgement and the selection of subjects. In fact, all the clinical expertise that goes into distinguishing an effective treatment is called upon in determining delta. The inclusion of sufficiently severe cases (e.g., with mood or anxiety disorders) is of fundamental importance to the successful separation of the effects of an active treatment from that of placebo. If patients with minor depression or anxiety symptoms are included in trials, the assay sensitivity is compromised, and the non-inferiority margin becomes too wide. If clinicians fail to observe an improvement or worsening of symptoms, the trial becomes useless on erroneous grounds.
Noninferiority studies are with us now. One consequence of this toughening regulation is that it obviates unexpected discoveries, such as that ciprofloxacin turned out to be effective in anthrax and typhoid fever. Most of the real drug discoveries in psychiatry were based on observations by experienced clinicians and not in phase II studies: MAOIs, chlorpromazine, lithium, desipramine and others. As for serendipity, who had expected the remarkable and unprecedented impact of zimelidine, fluoxetine, and their following antidepressant compounds on suicide rates, social functioning and health care cost?
The regulatory demands for noninferiority trials have become necessary as a consequence of the wide range of effective treatments available today, and the desire to minimize the use of placebo. They do, however, divert resource allocations from important diseases for which treatment outcomes are less predictable. They require sophisticated trial settings and such units are now being established in India.
Wine makers agree that to produce a guild-winning proprietor's blend takes both a wine and a think tank to optimise itthe same is true of noninferiority trials in psychiatry.
